275 related articles for article (PubMed ID: 18794797)
1. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
2. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
3. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
4. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
[TBL] [Abstract][Full Text] [Related]
6. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Wykosky J; Gibo DM; Debinski W
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715
[TBL] [Abstract][Full Text] [Related]
7. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas.
Binda E; Visioli A; Giani F; Lamorte G; Copetti M; Pitter KL; Huse JT; Cajola L; Zanetti N; DiMeco F; De Filippis L; Mangiola A; Maira G; Anile C; De Bonis P; Reynolds BA; Pasquale EB; Vescovi AL
Cancer Cell; 2012 Dec; 22(6):765-80. PubMed ID: 23238013
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.
Lema Tomé CM; Palma E; Ferluga S; Lowther WT; Hantgan R; Wykosky J; Debinski W
J Biol Chem; 2012 Apr; 287(17):14012-22. PubMed ID: 22362770
[TBL] [Abstract][Full Text] [Related]
9. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
10. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.
Greene AC; Lord SJ; Tian A; Rhodes C; Kai H; Groves JT
Biophys J; 2014 May; 106(10):2196-205. PubMed ID: 24853748
[TBL] [Abstract][Full Text] [Related]
11. The Expression of ephrinA1/ephA2 Receptor Increases in Chronic Rhinosinusitis and ephrinA1/ephA2 Signaling Affects Rhinovirus-Induced Innate Immunity in Human Sinonasal Epithelial Cells.
Lee SH; Kang SH; Han MS; Kwak JW; Kim HG; Lee TH; Lee DB; Kim TH
Front Immunol; 2021; 12():793517. PubMed ID: 34975898
[TBL] [Abstract][Full Text] [Related]
12. Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates erythropoietin expression after renal hypoxic injury.
Rodriguez S; Rudloff S; Koenig KF; Karthik S; Hoogewijs D; Huynh-Do U
Pflugers Arch; 2016 Aug; 468(8):1433-48. PubMed ID: 27228995
[TBL] [Abstract][Full Text] [Related]
13. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
14. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.
Beauchamp A; Lively MO; Mintz A; Gibo D; Wykosky J; Debinski W
Mol Cell Biol; 2012 Aug; 32(16):3253-64. PubMed ID: 22688511
[TBL] [Abstract][Full Text] [Related]
15. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
16. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility.
Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846
[TBL] [Abstract][Full Text] [Related]
17. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
Xu Q; Lin WC; Petit RS; Groves JT
Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062
[TBL] [Abstract][Full Text] [Related]
18. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of angiogenesis-related factors: CD105, EphA2 and EphrinA1 in laryngeal squamous cell carcinoma and clinical implication].
Su J; Ji XB; Xie JH; Li W
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 51(12):929-936. PubMed ID: 27978884
[No Abstract] [Full Text] [Related]
20. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
